Review

Antioxidants as precision weapons in war against cancer chemotherapy induced toxicity – Exploring the armoury of obscurity

Kanchanlata Singh a,⇑, Mustansir Bhor i a, Yasar Arfat Kasu a, Ganapathi Bhat b, Thankamani Marar a

a School of Biotechnology and Bioinformatics, D. Y. Patil Deemed to be University, CBD Belapur, Navi Mumbai, India
b Jaslok Hospital and Research Centre, Peddar Road, Mumbai, India

ARTICLE INFO

Article history:
Received 25 October 2017
Accepted 14 December 2017
Available online 19 December 2017

Keywords:
Antioxidant
Chemotherapy
Toxicity
Oxidative stress
Reactive oxygen species
Cancer

ABSTRACT

Cancer is the leading cause of mortality worldwide, accounting for almost 13% of deaths in the world. Among the conventional cancer treatments, chemotherapy is most frequently carried out to treat malignant cancer rather than localised lesions which is amenable to surgery and radiotherapy. However, anticancer drugs are associated with a plethora of side effects. Each drug, within every class, has its own set of adverse reactions which may cause patient incompliance and deterioration of the quality of life. One of the major causes of adverse reactions, especially for drugs targeting DNA, is the excessive production of reactive oxygen species (ROS) and subsequent build up of oxidative stress. To curb these undesired side effects, several dietary supplements have been tested, amongst which antioxidants have gained increasing popularity as adjuvant in chemotherapy. However, many oncologists discourage the use of antioxidant rich food supplements because these may interfere with the modalities which kill cancer by generating free radicals. In the present review, all studies reporting concomitant use of several antioxidants with chemotherapy are indiscriminately included and discussed impartially.

The effect of supplementation of thirteen different antioxidants and their analogues as a single agent or in combination with chemotherapy has been compiled in this article. The present review encompasses a total of 174 peer-reviewed original articles from 1967 till date comprising 93 clinical trials with a cumulative number of 18,208 patients, 56 animal studies and 35 in vitro studies. Our comprehensive data suggests that antioxidant has superior potential of ameliorating chemotherapeutic induced toxicity. Antioxidant supplementation during chemotherapy also promises higher therapeutic efficiency and increased survival times in patients.

© 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
1. Introduction

Antioxidants prevent cellular damage by reacting and eliminating oxidizing free radicals thereby finding relevance in adjuvant chemotherapy. The use of antioxidant supplements by patients with cancer is estimated to be between 13 and 87% (VandeCreek et al., 1999; Block et al., 2008). Such broad range of percentage might be attributed to the difference in cancer types, age, education, complementary medicines and ethnicity in the group undertaken for the study. The use of supra-dietary doses of antioxidant has attracted increasing interest as a possible primary and secondary cancer deterrence strategy. Higher levels of endogenous antioxidant may protect against chemotherapy induced oxidative stress especially in some cancer patients having impaired capacity to deal with oxidative insult (Conklin, 2004). However, in cancer chemotherapy, a mode of action of certain antineoplastic agents involves generation of free radicals further leading to cellular damage and necrosis of malignant cells. Hence use of antioxidant during chemotherapy is criticized due to fear of causing interference with efficacy of the drug. On the contrary, many integrative practitioner converse uses of antioxidant supplements allowing patients to tolerate possibly higher effective doses of chemotherapy thereby increasing the chance of better tumor response and improved survival rate. Thus concomitant use of antioxidant during chemotherapy is been highly controversial topic. The questions repeatedly put forth are “Do antioxidants increase or decrease the efficacy of anticancer agent? Do antioxidants protect normal tissue and ameliorate toxicity or protect cancer cells from the effect of chemotherapy”. This review intends to give a succinct idea about chemotherapy induced toxicity; ROS and oxidative damage followed with clarification on the major issue surrounding this controversy by reviewing the current state of understanding about potential and established interaction between antioxidant and conventional oncological therapies.

1.1. Chemotherapy

Chemotherapy is used primarily to treat systemic disease rather than localized lesions that are amenable to surgery or radiation. It uses antineoplastic agents in an attempt to destroy tumor cells by interfering with cellular function including replication. These drugs result in causing lethal injury to DNA which further leads to malignant cell death via apoptosis. In cancer treatment, mode of action of certain chemotherapeutic agents involves generation of free radicals to cause cellular damage and necrosis of malignant cells (Lamson and Brignall, 1999; Potmesil, 1994). Drugs with free radical mechanism include but are not limited to alkylating agent (alkylsulfonates, ethylenamines and hydrazines), anthracyclines (doxorubicin and doxorubicin), platinum coordination complexes (cisplatin, carboplatin), podophyll derivatives (etoposides) and camptothecins (irinotecan, topotecan). These ROS often are sources of atrocity side effects which remains as long as the duration of chemotherapy treatment (Joensuu, 2008).

1.2. Chemotherapy induced systemic toxicity

By its very nature, anti-cancer chemotherapy is cytotoxic that means it is designed to damage human cells. Because anti-cancer drugs are cytotoxic for normal as well as neoplastic cells, the range of unwanted effects that accompanies their use is broad. Many of the side-effects are potentially life-threatening or seriously debilitating. The precursor cells of the hemopoietic system, sited in the bone marrow, undergo cell division more rapidly than those of any other organ system and thus are particularly vulnerable to damage from cytotoxic drugs, since most chemotherapeutic agents act principally on dividing cells. Accordingly, bone marrow depression is a side-effect of nearly all such drugs and is the dose-limiting side effect of most. Red blood cell macrocytosis is a common effect of hydroxyurea, methotrexate, cytarabine and other antimitabolites.

Nausea and vomiting which usually occurs within 24 h of drug administration can be amongst the most disturbing and unpleasant side effects induced by chemotherapy. If persistent, vomiting may lead to dehydration, electrolyte disturbances, metabolic alkalosis, weakness, weight loss, cachexia, nutritional impairment and physical injury such as esophageal tears and fractures (Tortorice and Connell, 1990). Diarrhea and constipation in cancer patients may be due to many factors that include age, anticholinergics, narcotics, low fibre diet, decreased appetite and inability to eat and drink due to oral mucositis or esophagitis apart from the side-effects of cytotoxic drugs.

Cardiac damage is the dose-limiting toxicity of the anthracycline group of antitumor antibiotics related anthraquinones and can cause cumulative cardiomyopathy (Von Hoff et al., 1979). Damage to the liver is a complication of many drugs. Since patients receiving chemotherapy often are very ill and simultaneously receiving other medications that may impair liver function, it is often impossible to determine which of their treatments is responsible for the liver abnormality. Furthermore, septicemia, parenteral nutrition, viral and fungal infections and metastatic disease itself also commonly cause hepatic disturbance.

Pulmonary complications and kidney toxicity are being increasingly recognized and may be dose-limiting. Lung toxicity induced by methotrexate is said to occur in 5–8% of patients and includes pulmonary edema, pulmonary fibrosis, capillary leakage and hypersensitivity reaction (Bannwarth et al., 1994). The kidneys are vulnerable to damage from chemotherapeutic agents as they are the elimination pathway for many drugs and their metabolites. Cisplatin primarily causes proximal and distal tubular damage, although a rare hemolytic-uremic syndrome has also been reported (Daugaard et al., 1988).

Fertility problems can be an unfortunate delayed side effect of chemotherapy. Cytotoxic drugs damage the germinal epithelium resulting in reduced testicular volume and sperm count (Miller, 1971). The degree of dysfunction depends on the dose of drug as well as age and puberal status of the patient at the time of treatment (Sherins, 1993). Often chemotherapy mediated toxicities are related to generation of ROS leading to oxidative stress in cell.

1.3. Chemotherapy induced ROS and their intracellular sources

Most of the oxygen taken up by the cells is converted to water by the action of cellular enzymes. However, some of these enzymes leak electron into oxygen molecules and lead to the formation of free radicals. They are also formed during normal biochemical reactions involving oxygen. ROS is a collective term used for a
group of oxidants, which are either free radicals or molecular species capable of generating free radicals. There are two important sources of free radical formation. First the internal factors i.e. normal cellular metabolism like mitochondrial electron transport chain (ETC), endoplasmic reticulum oxidation and many enzymic activities. Other exogenous factors are radiation, chemotherapy, cigarette smoke and oxygen itself (Shinde et al., 2012).

Intracellular free radical mainly comprises superoxide radicals (O$_2^-$), hydroxyl radicals (OH$^-$), nitric oxide (NO$^-$), nitrogen dioxide (N$_2$O$^+$) and lipid peroxyl (LOO$^-$) radicals (Genestra, 2007). Under normal physiological conditions, nearly 2% of the oxygen consumed by the body is converted into O$_2^-$ through mitochondrial respiration, phagocytosis, etc. (Kunwar and Priyadararsi, 2011). Autooxidation of ubisemiquinone is the major source of superoxide anion (Han et al., 2001). Non radical or enzymic generation involves almost all oxidase enzymes (glycolate oxidase, D-amino acid oxidase, urate oxidase, acetyl-CoA oxidase, NADH oxidase and monoamine oxidase) generating H$_2$O$_2$ (Pourrahmad, 2002).

NO$^-$ is an endothelial relaxing factor and neurotransmitter, produced through nitric oxide synthase enzymes. NO$^-$ and O$_2^-$ radicals are converted to powerful oxidizing radicals like hydroxyl radical (·OH), alkoxy radical (RO$^-$), peroxyl radical (ROO$^-$), singlet oxygen (O$_2^+$) by complex transformation reactions. Some of the radical species are converted to molecular oxidants like hydrogen peroxide (H$_2$O$_2$), peroxynitrite (ONOO$^-$) and hypochlorous acid (HOCl). Sometimes these molecular species act as sources of ROS. NO$^-$ radical formation requires a cellular steady state level of both superoxide anion and H$_2$O$_2$. Precursors of hydroxyl radicals via Fenton reaction. ONOO$^-$ at physiological concentrations of carbon dioxide becomes a source of carbonate radical (CO$_3^-$) anion (Winterbourn, 2008). Thus, chemotherapy becomes a substantial but indirect source of generating free radicals resulting into oxidative damage.

1.4. ROS induced oxidative damage

Depending upon their nature, chemotherapy induced ROS reacts with biomolecules to produce different types of secondary radicals like lipid, sugar, nitrogenous base, amino acid derived radicals and thyl radicals [13]. These radicals in presence of oxygen are converted to peroxyl radicals that often induce chain reactions. The biological implications of such reactions depend on several factors like nature of the substrate, site of generation, activation of repair mechanisms, redox status etc (Winterbourn, 2008).

Cellular membranes are vulnerable to the oxidation by ROS due to the presence of high concentration of unsaturated fatty acids in their lipid components. ROS reactions with membrane lipids cause lipid peroxidation, resulting in formation of lipid hydroperoxide (LOOH) which can further decompose to an aldehyde such as malondialdehyde, 4-hydroxy nonenal (4-HNE) or cyclic endoperoxide, isoprostans and hydrocarbons. The consequences of lipid peroxidation are cross linking of membrane proteins, change in membrane fluidity and formation of lipid-protein, lipid-DNA adduct which may be detrimental to the functioning of cell (Conklin, 2004).

The side chains of all amino acid residues of proteins, in particular tryptophan, cysteine and methionine are susceptible to oxidation by ROS. Protein oxidation products are usually carbonyls such as aldehydes and ketones. Proteins can undergo direct and indirect damage following interaction with ROS resulting into peroxidation, changes in their tertiary structure, proteolytic degradation, protein-protein cross linkages and fragmentation (Beckman and Ames, 1997).

Although DNA is a stable and well-protected molecule, ROS can interact with it and cause several types of damage such as modification of DNA bases, single and double strand DNA breaks, loss of purines, damage to the deoxyribose sugar, DNA-protein cross-linkage and damage to the DNA repair systems (Beckman and Ames, 1997). Free radicals can also attack the sugar moiety, which can produce sugar peroxyl radicals and subsequently inducing strand breakage. The consequence of DNA damage is the modification of genetic material resulting in cell death, mutagenesis and ageing.

1.5. Redox state and oxidative stress

All forms of life maintain a steady state concentration of ROS determined by the balance between their rates of production and removal by various antioxidants. Each cell is characterized by a particular concentration of reducing species like GSH, NADH, FADH$_2$ etc., stored in many cellular constituents, which determine the redox state of a cell (Kohen and Nyska, 2002). By definition, redox state is the total reduction potential or the reducing capacity of all the redox couples such as GSSH/2GSH, NAD$^+/$/NADH found in biological fluids, organelles, cells or tissues (Schafar and Bielke, 2001). Redox state not only describes the state of a redox pair, but also the redox environment of a cell. Under normal conditions, the redox state of a biological system is maintained towards more negative redox potential values. However, this balance can be disturbed when level of ROS exceeds and/or levels of antioxidants are diminished. This state is called ‘oxidative stress’ and can result in serious cellular damage or apoptosis of normal cells if the stress is massive and prolonged (Pham-Huy et al., 2008).

In contrast to oxidative stress-induced apoptosis, excessive oxidative stress inhibits caspase activity and drug-induced apoptosis, thereby interfering with the ability of antineoplastic agents to kill tumor cells. Electrophilic aldehydes, such as tetrapeptide aldehyde (acetyl-Tyr-Val-Ala-Asp-H) that are used to characterize caspase-1, covalently bind to the sulfhydryl group of the cysteine residue at the active site of caspases and inhibit their activity. Thus during oxidative stress, aldehyde generation resulting in caspase inhibition may account for the reduced efficacy of antineoplastic agents. If so, antioxidants may enhance the anticancer activity of cancer chemotherapy by reducing aldehyde generation during chemotherapy-induced oxidative stress (Conklin, 2004).

2. Antioxidant system

In order to check the activities of ROS/RNS in vivo and maintain cellular redox homeostasis, antioxidant system has evolved. Antioxidants are substances that may protect cells from the damage caused by free radicals, and may play a role in heart disease, cancer and other diseases. Antioxidants neutralize free radicals by donating one of their own electrons and ending the electron "stealing" reaction. This helps to prevent ROS mediated cell and tissue damage. Antioxidants are often described as “mopping up” free radicals, meaning they neutralize the electrical charge and prevent the free radical from taking electrons from other molecules (Bjelakovic, 2007).

Endogenous compounds in cells can be classified as enzymatic antioxidants such as superoxide dismutase, catalase, glutathione dependent enzymes and non-enzymatic antioxidants, further divided into metabolic and nutrient antioxidants. Metabolic antioxidants belonging to endogenous antioxidants such as GSH, lipoic acid, L-arginine, Coenzyme Q10, melatonin, uric acid, bilirubin etc. are produced by metabolism in the body. Nutrient antioxidant belonging to exogenous antioxidants which are taken through food supplements are vitamin E, vitamin C, carotenoids, trace elements, flavonoids, polyphenols etc. (Valko et al., 2007; Alexieva et al., 2010). A delicate balance exists between antioxidant repairing systems and pro-oxidant mechanism of tissue
destruction, which if tipped in favour of cellular damage, could lead to significant tissue mutilation (Sharma and Sharma, 2011).

2.1. Chemotherapy, oxidative stress and antioxidants

Chemotherapy drugs that cause high levels of oxidative stress are thought to rely, in part, on using this stress mechanism to kill cancer cells. But oxidative stress might actually reduce the overall effectiveness of chemotherapy. Oxidative stress slows the process of cell replication, but it is during cell replication that chemotherapy actually kills cancer cells, so slower cell replication can mean lower effectiveness of chemotherapy (Conklin, 2004). One approach towards addressing this problem is the addition of certain antioxidants at specific dosages to lessen oxidative stress, thus making the chemotherapy treatment more effective (Perumal et al., 2005). The interaction between chemotherapy and antioxidants is more complex than simply promoting and inhibiting oxidative stress. However, there are several mechanisms by which chemotherapy functions and antioxidants also have a number of different effects on the body. Each antioxidant has a different interaction in chemotherapy and this effect can even change based upon the dosage used.

Some antioxidants have been found to be useful for restoring the natural antioxidants in the body, which are often depleted after the completion of chemotherapy, resulting in decreased side effects and increased the survival time in patients undergoing chemotherapy. Thus, targeted nutrient therapies using antioxidant or their precursors can prove to be beneficial in reducing the toxic effect of medications thereby improving the therapeutic efficacy.

2.2. Antioxidants in chemotherapy

Role of antioxidants are controversial in cancer therapy because of two very imperative features “First, there are two different kinds of antioxidants doses used based on which the data on the role of antioxidants in cancer therapy can be categorized as: a preventive dose, which is a low dose, and a therapeutic dose, which is a high dose. For the preventive dose, the data has shown protection of normal cells and tumor cells. For the therapeutic dose, the data shows that it inhibits the growth of cancer cells but not the normal cells. Therefore researchers are looking at data for preventive doses, which is perplexing.

Numerous original research articles have focused on the topic of whether supplemental antioxidant administrated during chemotherapy can protect normal tissue without adversely influencing tumor control. Due to variation in study design, intervention protocol, cancer type, timing of observation, inclusive criteria, statistical analysis, chemotherapy regime develops uncertainty to make definitive conclusion regarding the risk of decreased tumor control as a consequence of administering supplemental antioxidant during chemotherapy. On the contrary certain recent review definitely concludes that that antioxidant when given concurrently (a) do not interfere with chemotherapy, (b) enhance the cytotoxic effect of chemotherapy, (c) protects normal tissue and (d) increases patient survival and therapeutic response (Simone et al., 2007a; Simone et al., 2007b).

Moss in the year 2007, investigated articles and reviews to find out the use of α-tocopherol for the amelioration of radiation-induced mucositis; pentoxifylline and vitamin E to correct the adverse effects of radiotherapy; melatonin alongside radiotherapy in the treatment of brain cancer; retinol palmitate as a treatment for radiation-induced proctopathy; a combination of antioxidants (and other naturopathic treatments) and the use of synthetic antioxidants like amifostine and dexrazoxane, as radioprotectants. With few exceptions, most of the studies draw positive conclusions about the interaction of antioxidants and radiotherapy (Moss, 2007).

Currently, evidence is growing that antioxidants may provide some benefit when combined with certain types of chemotherapy. Because of the potential for positive benefits, a randomized controlled trial evaluating the safety and efficacy of adding antioxidants to chemotherapy in newly diagnosed ovarian cancer is underway at the University of Kansas Medical Center (Drisko et al., 2003). In Long Island breast cancer patient study project, Greenlee and colleagues have reported that among 764 patients, 663 (86.8%) were found to be receiving adjuvant treatment for their breast cancer. Of those 663 women, 401 (60.5%) reported using antioxidants during adjuvant treatment. 210 of 310 women (67.4%) used antioxidants during chemotherapy, 196 of 464 women (42.2%) used them during radiation, and 286 of 462 women (61.9%) used them during tamoxifen therapy (Greenlee et al., 2009). In year 2012, same group published a data investigating the associations between antioxidant use after breast cancer diagnosis and breast cancer outcomes in 2264 women. Antioxidant supplement use after diagnosis was reported by 81% of women. Among antioxidant users, frequent use of vitamin C and vitamin E was associated with decreased risk of BC recurrence, vitamin E use was associated with decreased risk of all cause mortality but conversely, frequent use of combination carotenoids was associated with increased risk of death from breast cancer and all cause mortality (Greenlee et al., 2012).

A report on population-based prospective cohort study of 4877 women was conducted in the first 6 months after breast cancer diagnosis and during cancer treatment with total mortality and recurrence. Vitamin use shortly after breast cancer diagnosis was found to be associated with reduced mortality and recurrence risk, adjusted for multiple lifestyle factors, sociodemographics, and known clinical prognostic factors. Researchers concluded that vitamin supplement use in the first 6 months after breast cancer diagnosis may be associated with reduced risk of mortality and recurrence (Nechuta et al., 2011).

Cancer patients suffer from vitamin deficiencies, particularly of folic acid, vitamin C, pyridoxine and other nutrients because of poor nutrition and treatment. Chemotherapy reduces serum levels of antioxidant vitamins and minerals due to lipid peroxidation and thus produces higher level of oxidative stress. Therefore, supplementation of certain antioxidants and nutrients can help to enhance the health status of patients undergoing continuous regime of chemotherapy (Drisko et al., 2003). Vitamin E has been shown to decrease chemotherapy mediated toxicity and with omega-3 fatty acid increase survival time in terminal cancer patients. Other than suppressing free radical induced progression of lipid peroxidation in normal cells, vitamin E is also known to induce apoptosis in experimental tumor lines and increase the efficacy of chemotherapy (Lamson and Brignall, 1999).

Kline et al. have reported approximately 50 vitamin E analogues being synthesized and screened for their ability to induce human tumor cells to undergo apoptosis (Kline et al., 2004). Eleven vitamin E analogues exhibited to have potent anticancer properties. Liposome-formulated α-TEA administered to BALB/c mice by aerosol for 17 days significantly reduced subcutaneous injected mouse mammary tumor cells growth and lung metastasis. Tumor volume was reduced by 65% in comparison with the aerosol control. Schwenke concluded that dietary exposure to α-tocopherol may modestly protect women from breast cancer. Some reports have suggested that vitamin E succinate (VES) inhibits the growth of human breast cancer in culture by induction of DNA synthesis arrest, cellular differentiation and apoptosis (Schwenke, 2002). The authors here wish to emphasize that combinations not studied in vivo risk potential adverse reactions and should be monitored closely.
Table 1
Effect of fat and water soluble vitamin supplementation in combination with different chemotherapeutic agents in various clinical trials as well as in vivo and in vitro studies.

| Antioxidant | Type of chemotherapy | Type of study (n) | Toxicity mitigation | Higher therapeutic response rate | Increased survival | Author (reference) |
|-------------|----------------------|------------------|---------------------|----------------------------------|-------------------|--------------------|
| Vitamin A   | Cyclophosphamide     | Animal           | Yes                 | Yes but decreased therapeutic effect in fibrosarcoma, no change in squamous carcinoma | Yes               | Seifter et al. (1984) |
| Vitamin A   | β-carotene           | Animal           | –                   | –                                | –                 | –                  |
| Vitamin A, β-carotene | 5-fluorouracil, Cyclophosphamide, 4-Hydroperoxycyclophosphamide, melphalan | Animal and In vitro | –                   | Yes                             | –                 | Teicher et al. (1994) |
| Vitamin A   | Doxorubicin, Bleomycin, 5-fluorouracil, Methotrexate | Human (25) | Yes                 | Yes                             | More sensitive    | Thatcher et al. (1980) |
| Vitamin A   | Doxorubicin and Etoposide | In vitro         | –                   | Yes                             | –                 | Doyle et al. (1989), Adwankar et al. (1991) |
| Vitamin A   | Doxorubicin, Cisplatin and Vincristine | In vitro         | –                   | Increased cytotoxic effect, Increased cell differentiation and more sensitive to DOX | –                 | –                  |
| Vitamin A   | Methotrexate, Etoposide, Cisplatin | Animal Human (22) | Yes                 | No difference                   | No difference     | Nagai et al. (1993), Kalemkerian et al. (1998), Adwankar et al. (1991), Recchia et al. (1998), Budd et al. (1998) |
| Vitamin A   | Vincristine          | In vitro         | –                   | Increased cytotoxic effect       | –                 | –                  |
| Vitamin A   | Tamoxifen            | Human (25)       | –                   | Yes                             | –                 | –                  |
| Vitamin A   | 5-fluorouracil, Bleomycin, Doxorubicin, Mitomycin-C 5-fluorouracil | Human (100) | Yes                 | Yes                             | Yes               | Israel et al. (1985) |
| Vitamin A   | Busulfan             | Human (1 53)     | Yes                 | Yes                             | Yes               | Mestikens et al. (1993), Recchia et al. (1993) |
| Vitamin A   | Cisplatin, Vindesine, 5-fluorouracil, Interferon 5-fluorouracil, Cisplatin | Human (40) | Yes                 | Yes                             | Yes               | Recchia et al. (1993b) |
| Vitamin A   | Cyclophosphamide, 5-fluorouracil, Vincristine, Prednisone, Methotrexate, Mitomycin-C, Mitoxantrone, Tamoxifen | Human (36) | Yes                 | Yes                             | –                 | Recchia et al. (1995) |
| Vitamin A   | 5-fluorouracil, Epirubicin, Mitomycin-C, Interferon, Tamoxifen | Human (22) | No difference       | No difference                   | No difference     | Recchia et al. (1992) |
| Vitamin A   | Tamoxifen            | Human (49)       | Yes                 | Yes                             | Yes               | Recchia et al. (1995) |
| β-Carotene  | Vincristine, Methotrexate, Bleomycin Chemotherapy | Human (20) | Yes                 | No difference                   | No difference Yes | Mills EE et al. (1988), Santamaria et al. (1996) |
| β-carotene  | Vincristine          | Human (15)       | Yes                 | Yes                             | Yes               | Santamaria et al. (1996) |
| Vitamin C   | Doxorubicin, Cisplatin, Paclitaxel | In vitro         | –                   | Synergistically Increasing cytotoxic effect | –                 | Kurbacher et al. (1996) |
| Vitamin C   | Vincristine          | Animal (20)      | –                   | Yes                             | –                 | Taper et al. (1987) |
| Vitamin C   | Doxorubicin          | Animal (20)      | –                   | Yes                             | Yes               | Shimo et al. (1991) |
| Vitamin C   | 5-fluorouracil, Bleomycin Methotrexate | Animal (20) | Yes                 | –                               | Increased cytotoxic effect | Prasad et al. (1999) |
| Vitamin C   | Cisplatin            | Human (48)       | No difference       | –                               | –                 | Weiji et al. (2004) |
| Vitamin C   | Cyclophosphamide, Methotrexate, 5-fluorouracil Doxorubicin | Human (30) | –                   | Yes                             | –                 | Goel et al. (1999) |
| Vitamin C   | Doxorubicin          | Animal (30)      | Yes                 | –                               | –                 | Swamy et al. (2011) |
| Vitamin E   | Cyclophosphamide     | Animal (30)      | –                   | Yes                             | –                 | Vinitha et al. (1995) |
| Vitamin E   | Doxorubicin, 5-fluorouracil | Animal (30) | Yes                 | –                               | Vinitha et al. (1995) |
| Vitamin E   | Doxorubicin          | Animal (30)      | Yes                 | Yes                             | Cytotoxic effect  | Chinery et al. (1997) |
| Vitamin E   | Doxorubicin, Methotrexate, Vincristine | In vitro Animal | –                   | Yes                             | –                 | Perez Ripoll et al. (1986) |
| Vitamin E   | Cisplatin            | Animal (30)      | Yes                 | –                               | –                 | Sue et al. (1988), Argyriou et al. (2006) |
| Vitamin E   | Cyclophosphamide, Doxorubicin, 5-fluorouracil | Human (30) | No difference       | No difference                   | –                 | Legha et al. (1982) |

(continued on next page)
| Antioxidant | Type of chemotherapy | Type of study (n) | Toxicity mitigation | Higher therapeutic response rate | Increased survival | Author (reference) |
|-------------|---------------------|-----------------|--------------------|---------------------------------|-------------------|-------------------|
| Vitamin E   | Doxorubicin         | Human (12)      | Yes                | Yes                             | –                 | Lenzhofer et al. (1983) |
| Vitamin E   | Chemotherapy for acute myelogenous leukemia, transplant Doxorubicin | Human (20) | Yes                | Yes                             | –                 | Lopez et al. (1994)   |
| Vitamin E   | 13-Cis retinoic acid | Human (16)      | No Difference      | No Difference                   | No Difference     | Weitzman et al. (1980) |
| Vitamin E   | 13-Cis retinoic acid | Human (66)      | Yes                | Yes                             | –                 | Besa et al. (1990)   |
| Vitamin E   | All trans retinoic acid, erythropoietin | Human (17) | Yes                | Yes                             | –                 | Ganser et al. (1996) |
| Vitamin E   | Cyclophosphamide, Adriamycin, 5-fluorouracil Doxorubicin, Nifedipine | Human (12) | Yes                | Yes                             | –                 | Durken et al. (1995) |
| Vitamin E   | 5-fluorouracil, Cisplatin, Doxorubicin, Arabinosyl cytosine | Human (18) | Yes                | Yes                             | –                 | Erhola et al. (1996) |
| Vitamin E   | Adriamycin          | Human (16)      | No difference      | No difference                   | –                 | Erhola et al. (1998) |
| Vitamin E   | Adriamycin          | Human (18)      | Yes                | Yes                             | –                 | Wood et al. (1985)   |
| Vitamin E   | Doxorubicin         | Animal          | Yes                | Yes                             | Yes               | Myers et al. (1977)  |
| Vitamin E   | Doxorubicin         | Animal          | Yes                | –                               | Yes               | Sonneveld et al. (1978) |
| Vitamin E   | Camptothecin        | Animal          | Yes                | –                               | Yes               | Singh et al. (2011, 2011a, 2011b, 2012) |
| Vitamin E   | Camptothecin        | In vitro        | Yes                | –                               | Yes               | Singh et al. (2012b, 2013) |
| Vitamin E   | Methotrexate        | Doxorubicin     | Yes                | –                               | –                 | Singh et al. (2012a) |
| Vitamin E   | Bleomycin, 5- fluorouracil, Adriamycin, Cisplatin,mutamycin, CCNU, DTIC, Chloroztocin | In vitro | –                  | Yes                             | –                 | Prasad et al. (1999) |
| Vitamin E   | Cisplatin           | Human (27)      | Yes                | No difference                   | No difference     | Pace et al. (2003)   |
| Vitamin E   | Cisplatin, Carboplatin, Oxaliplatin and combination Paclitaxel | Human (207) | No difference      | No difference                   | No difference     | Kottschade et al. (2011) |
| Vitamin E   | Doxorubicin         | Animal          | Yes                | –                               | Yes               | Argyriou et al. (2006) |
| Vitamin E   | Doxorubicin         | Animal          | Yes                | –                               | –                 | Geetha and Devi (1992) |
| Vitamin E   | Cisplatin, Hexamethylamine | Human (6300) | Yes                | Yes                             | –                 | Ladner and Salkeld (1988) |
| High dose pyrroline | Chemotherapy | Human (248) | Yes                | –                               | –                 | Wiernik et al. (1992) |
| Menadione (Vitamin D analogue) | Mitoymycin-C | Human (51) | Yes                | Yes                             | –                 | Margolin et al. (1995) |
| Vitamin K<sub>3</sub> | Chemotherapy | Human (14) | Yes                | Yes                             | –                 | Nagourney et al. (1987) Milczarek et al. (2013) |
| Vitamin D and analogues (PRI-2191 AND PRI-2205) | 5-fluorouracil | Animal | Yes                | Yes                             | Yes               | Milczarek et al. (2013) |
| Vitamin D<sub>3</sub> | Cisplatin | In vitro | –                  | Yes                             | –                 | Bao et al. (2014) Milczarek et al. (2013) |
| Vitamin D analogues | Irinotecan | Animal | –                  | Yes                             | Yes               | –                 | Switalska et al. (2012) |
| Vitamin D analogues | Oxaliplatin | Animal | –                  | Yes                             | –                 | Milczarek et al. (2013) |
| Vitamin D analogue (PRI-2191) | Imatinib mesylate | In vitro | –                  | Yes                             | –                 | Yoshida et al. (2003) Parekhi et al. (1991) |
| Vitamin D<sub>3</sub> | Cisplatin | In vitro | –                  | Yes                             | Yes               | –                 | Crim et al. (1967) Wiertzyn et al. (2008) |
| Vitamin D<sub>3</sub> | Adriamycin | In vitro | Yes                | –                               | Yes               | –                 | Bello et al. (2009) |
| Vitamin B   | Cisplatin          | Animal          | Yes (at lower dose) | Yes                             | –                 | Guneri et al. (2001) |

(n) = number of subjects involved in clinical study.
The following tables summarize the effect of various antioxidants when combined with specific chemotherapeutic agents.

**Table 1** represents data collected from a total of seventy-five peer reviewed research articles which investigated the concurrent use of fat and water soluble antioxidants with chemotherapy. Amongst them total number of clinical trials is 36 which had involvement of 8047 patients (males and females both). Total number of articles on in vitro and animal model are 19 and 28 respectively. Table represents use of 5 different vitamins in their various forms along with 34 different chemotherapeutic agents in a specific combination. 21 research papers explore concurrent use of vitamin A with 14 different chemotherapeutic agents used individually or in combination.

**Table 2**

| Antioxidant Type of chemotherapy | Type of study (n) | Toxicity mitigation | Higher therapeutic response rate | Increased survival | Author (reference) |
|----------------------------------|------------------|---------------------|----------------------------------|-------------------|-------------------|
| GSH Cyclophosphamide, Cisplatin | Human (79)       | Yes                 | No difference                     | Yes               | –                 |
| GSH Cyclophosphamide, Cisplatin | Human (20)       | Yes                 | No difference                     | –                 | Locatelli et al. (1993) |
| GSH Epirubicin, Cisplatin, 5-fluorouracil | Human (50) | –                   | Yes                               | –                 | Zhang et al. (1999) |
| GSH 5-fluorouracil | Animal           | Yes                 | No difference                     | –                 | Cascinu et al. (1988) |
| GSH 5-fluorouracil | Animal           | Yes                 | No difference                     | –                 | Danyasz et al. (1984) |
| GSH Cisplatin | Human (151) | Yes                 | Possible                          | No difference     | Smyth et al. (1997) |
| GSH Cisplatin | Human (24)       | Yes                 | Possible                          | No difference     | Cascinu et al. (1995) |
| GSH Cisplatin, Carboplatin | Human (50)       | Yes                 | Yes                               | –                 | Bohm et al. (1999) |
| GSH Cisplatin, Cyclophosphamide | Human (35)       | Yes                 | Yes                               | –                 | Bohm et al. (1999) |
| GSH 5-fluorouracil and Cisplatin | Human (11) | –                   | –                                 | –                 | Cozzaglio et al. (1990) |
| GSH Cisplatin, Cyclophosphamide | Human (40)       | Yes                 | Yes                               | –                 | Di Re et al. (1990) |
| GSH Cisplatin, Bleomycin | Human (12)       | Yes                 | Yes                               | –                 | Leone et al. (1992) |
| GSH Cyclophosphamide | Human | –                   | Yes                               | –                 | Noble et al. (1989) |
| GSH Cisplatin, Cyclophosphamide | Human (16)       | Yes                 | –                                 | –                 | Oriana et al. (1987) |
| GSH Cisplatin | Human (52)       | Yes                 | No difference                     | –                 | Cacini et al. (2002) |
| GSH Cisplatin, 5-fluorouracil | Human (20)       | Yes                 | No difference                     | No difference     | Schmidinger et al. (2000) |
| GSH Mitomycin-C, 5-fluorouracil and Phenobarbital | Human (207) | No difference | No difference                     | Yes               | Fujimoto et al. (1983) |
| GSH Cisplatin | Human (33)       | Yes                 | No difference                     | No difference     | Colombo et al. (1995) |
| Melatonin Cyclophosphamide | Animal           | Yes                 | No change in therapeutic effect   | No difference     | Musatov et al. (1997) |
| Melatonin Cisplatin, Etoposide | Human (70)       | Yes                 | No difference                     | Yes               | Lissoni et al. (1997) |
| Melatonin Cisplatin, Etoposide | Human (20)       | Yes                 | –                                 | Yes               | Ghielmini et al. (1990) |
| Melatonin Epirubicin | Human (12)       | Yes                 | –                                 | –                 | Lissoni et al. (1999) |
| Melatonin Tamoxifen | Human (14)       | Yes                 | Partial                           | –                 | Lissoni et al. (1995) |
| Melatonin Tamoxifen | Human (25)       | Yes                 | Partial                           | Yes               | Lissoni et al. (1996) |
| Melatonin Interleukin-2 | Human           | Yes                 | Synergistic                       | –                 | Lissoni et al. (1994) |
| Melatonin Cisplatin and Etoposide | Human (100) | –                   | Yes                               | –                 | Lissoni et al. (2003) |
| Melatonin Non – small cell lung: Cisplatin, Etoposide and Gemcitabine Breast: Doxorubicin, Mitoxantrone and Paclitaxel; Gastrointestinal: 5 FU & folic acid. Head and neck cancer: 5-fluorouracil and Cisplatin | Human (250) | Yes                 | No difference                     | Yes               | Lissoni et al. (1993) |
| Melatonin Irinotecan | Human (30)       | No difference       | No difference                     | No difference     | Cerea et al. (2003) |
| Melatonin Cytarabine, Daunorubicin, and Etoposide | In vitro | No difference | No difference                     | No difference     | Mustafa et al. (2011) |
| Melatonin Vincristine / Isophosphamide | In vitro | Yes                 | Yes                               | –                 | Casada-Zapico et al. (2010) |
| NAC Isophosphamide | Human           | Yes                 | No difference                     | –                 | Slavik and Saiers (1983) |
| NAC Isophosphamide | Human           | Yes                 | No difference                     | –                 | Hooley et al. (1983) |
| NAC Cyclophosphamide | Animal          | Yes                 | No difference                     | –                 | Levy and Vredevoe (1983) |
| NAC Cyclophosphamide | Animal          | Yes                 | No difference                     | –                 | [150] |
| NAC Doxorubicin | Human (24)       | Yes                 | No difference                     | –                 | Harrison et al. (1983) |
| NAC Doxorubicin | Human           | Yes                 | No difference                     | –                 | Palermo et al. (1986) |
| NAC Doxorubicin | Human           | Yes                 | No difference                     | –                 | Myres et al. (1983), Unverferth et al. (1983) |
| NAC Doxorubicin | Human           | Yes                 | No difference                     | –                 | Olson et al. (1983) |
| NAC Doxorubicin | Human           | Yes                 | No difference                     | –                 | Schmitt-Graff and Scheulen (1986) |
| NAC Doxorubicin | Human           | Yes                 | No difference                     | –                 | Roller and Weller (1998) |
| NAC Doxorubicin | Human           | Yes                 | No difference                     | –                 | Miyajima et al. (1999) |
| NAC Doxorubicin | Human           | Yes                 | No difference                     | –                 | Dickey et al. (2005) |

(n) = number of subjects involved in clinical study; GSH (Glutathione); NAC (N-Acetylcystein).
Vitamin C has been used as an adjunct antioxidant in 9 research articles of which 5 articles report its excellent synergistic and increased therapeutic effect. 34 articles have investigated the effectiveness of vitamin E in cancer chemotherapeutics of which 28 articles states that drug induced toxicity was efficiently ameliorated due to supplementation of vitamin E. Only few research articles on vitamin D and its analogues (9), vitamin K (3) and vitamin B (5) was found. Of all 75 research articles, 53 articles (70%) reports remarkable antioxidant mediated toxicity mitigation and rest 27 reports suggest no changes in the data or toxicity related studies was not applicable in the report. Therapeutic response after coadministration of antioxidant was also studied and was found out that 49 (65%) research articles has mentioned that antioxidant supplementation increases therapeutic efficiency and 15 (20%) articles reports increase in survival time.

Table 2 represents data collected from a total of forty-six peer reviewed research article which explored the consequences of antioxidants like GSH, melatonin and NAC in chemotherapeutics. Amongst them total number of clinical trial is 32 which had participation of 1415 subjects male and female both. Total number of articles on in vitro and animal model are 5 and 8 respectively. These 3 antioxidants are used in specific combination with 22 different chemotherapeutic agents. The combination of GSH and chemotherapy is the most studied category in our results (23 out of 46). The antioxidant substances were described as either “glutathione” or reduced glutathione. 12 out of 46 reports suggested use of melatonin in cancer chemotherapy and rest 11 reports are on co-supplementation of NAC along with cancer treating drugs. Of all 46 reports, 35 (76%) articles states that antioxidant administration mitigates drug induced toxicity which indicate superior potential of all 3 antioxidant in clinical and in vitro settings. 12 (26%) reports confirms higher therapeutic response upon antioxidant supplementation, 4 reports have published possible or partial usefulness of these antioxidants during chemotherapy and rest 29 articles suggest no possible role of antioxidant in enhancing the therapeutic response. Few (6) reports also reveals increased survival of subjects when provided with antioxidant along with chemotherapy.

Table 3 represents data assembled from 26 peer-reviewed research article which focuses on understanding the role of antioxidants like Quercetin, Selenium and Coenzyme Q10 during chemotherapy. This data comprises of 6 clinical studies engaging 270 subjects (both male and female), 15 animal studies, and 8 studies on in vitro model. 10 different chemotherapeutic agents were used individually or in combination with above listed all three antioxidants. 5 research articles explain the effect of quercetin in chemotherapy of which all 5 research submissions suggests higher therapeutic response rate in presence of antioxidant. Out of 10 reports on selenium, 8 articles (80%) unfolded the fact of coadministration of selenium along with different chemotherapeutic agent results in superior mitigation of toxicity induced during ther-

| Antioxidant | Type of chemotherapy | Type of study (n) | Toxicity mitigation | Increased survival | Author (Reference) |
|-------------|----------------------|------------------|--------------------|-------------------|-------------------|
| Quercetin   | Busulfan, Cisplatin  | Animal and In vitro | –                  | Yes               | Scambia et al. (1992) |
| Quercetin   | Doxorubicin, Daunorubicin | In vitro          | –                  | Increased cytotoxic effect | Scambia et al. (1994), Critchfield et al. (1994), Versantvoort et al. (1993) |
| Selenium   | Melphalan            | In vitro          | Yes                | No difference     | Hofmann et al. (1990) |
| Selenium   | Doxorubicin          | Animal            | Yes                | –                 | Tobey and Tesmer (1985) |
| Selenium   | Doxorubicin          | Animal            | Yes                | –                 | Boucher et al. (1995) |
| Selenium   | Doxorubicin          | Animal            | –                  | Yes               | Coudray et al. (1995) |
| Selenium   | Methotrexate         | Animal            | –                  | Yes               | Milner et al. (1981) |
| Selenium   | Cisplatin            | Human (41)        | Yes                | –                 | Hu et al. (1997) |
| Selenium   | Cisplatin            | Animal            | Yes                | Yes               | Nagamura et al. (1984) |
| Selenium   | Cisplatin            | Animal            | Yes                | Yes               | Berry et al. (1984) |
| Selenium   | Cyclophosphamide     | Animal            | Yes                | Yes               | Ohkawa et al. (1988) |
| Co-enzyme Q10 | Cyclophosphamide + Doxorubicin + 5-fluourouracil | Animal (Combined therapy) | Yes                | Yes               | Chakrabharty et al. (2009) |
| Co-enzyme Q10 | Cyclophosphamide + OK432 | Animal (Combined therapy) | Yes                | Yes               | Takimoto et al. (1982) |
| Co-enzyme Q10 | Doxorubicin          | Human (10)        | Yes                | No difference     | Kokawa et al. (1983) |
| Co-enzyme Q10 | Doxorubicin          | Human (80)        | Yes                | No difference     | Cortes et al. (1978) |
| Co-enzyme Q10 | Doxorubicin          | Animal            | Yes                | No difference     | Okuma et al. (1984) |
| Co-enzyme Q10 | Tamoxifen            | Animal            | –                  | Yes               | Slaaper et al. (1980) |
| Co-enzyme Q10 | Doxorubicin          | Human (79)        | Yes                | Yes               | Perumal et al. (2005) |
| Co-enzyme Q10 | Doxorubicin          | Human (20)        | Yes                | –                 | Tsukagi et al. (1984) |
| Co-enzyme Q10 | Doxorubicin, Daunorubicin | Animal            | –                  | –                 | Iarussi et al. (1994) |
| Co-enzyme Q10 | Doxorubicin          | Animal            | Yes                | –                 | El-Sheikh et al. (2012) |
| Co-enzyme Q10 | Cisplatin            | Animal (32)       | Yes                | –                 | Fouad et al. (2010) |
| Co-enzyme Q10 | Doxorubicin          | In vitro          | Yes                | No difference     | Greenlee et al. (2012) |
Combinatorial effect of a mixture of antioxidants with different chemotherapeutic agents in various clinical trials as well as in vivo studies. Out of 22, 16 articles (72%) emphasize on toxicity in vitro including 571 subjects, 4 animal studies and 3 experiments on chemotherapeutic agents. This data represent 15 clinical trials of chemotherapy regime including 17 different types of combination at a particular dose were combined with antioxidant individually. A total of 15 antioxidants in a specific mixture of antioxidants can be more beneficial than using this along with cancer treating drugs. Many research articles pose incorporation which analyses the outcome of mixture of antioxidant mediated toxicity mitigation and rest 8 articles published no antioxidants supplementation in order to alleviate drug induced toxicity.

In Table 4, data from twenty-two research submissions are incorporated which analyses the outcome of mixture of antioxidant along with cancer treating drugs. Many research articles pose that mixture of antioxidants can be more beneficial than using this antioxidants individually. A total of 15 antioxidants in a specific combination at a particular dose were combined with a well scheduled chemotherapy regime including 17 different types of chemotherapeutic agents. This data represent 15 clinical trials including 571 subjects, 4 animal studies and 3 experiments on in vitro model. Out of 22, 16 articles (72%) emphasis on toxicity amelioration by antioxidant mixture during therapy, 15 research papers reports increased therapeutic response and 5 states there was increase in the survival time after antioxidant administration.

3. Conclusion

This review constitutes a total of 174 peer-reviewed original articles from 1967 till date comprising 93 clinical trials with a cumulative number of 18,208 subjects, 56 animal and 35 in vitro studies. Out of total cases reported in 174 research articles, 138 research papers have reported consequences of antioxidant supplementation during or after chemotherapeutic setting of which 122 articles (88%) states that antioxidants mitigates the toxicities not interfere with chemotherapy and can be prescribed during clinical setting to increase the standard of life.

| Antioxidants Type of chemotherapy | Type of study (n) | Toxicity mitigation | Higher therapeutic response rate | Increased survival | Author (reference) |
|----------------------------------|------------------|---------------------|---------------------------------|------------------|-------------------|
| Vit C and K3 5-fluorouracil       | Human (18)       | Yes                 | Yes                             | –                | Taper et al. (1987) |
| Beta carotene, Vit A, Vit C, Vit E | In vitro         | –                   | Increased cytotoxic effect       | Yes              | Prasad et al. (1994) |
| Vit A, Beta carotene, Thiamine, Riboflavin, Pyridoxine, Vit B12, Vit D, Vit C, Calcium and Biotin | Human (18)       | Yes                 | Yes                             | Yes              | Jakkola et al. (1992) |
| Vit C, Vit E and GSH              | Human (36)       | Yes                 | Yes                             | –                | Osaki et al. (1994) |
| Vit A and Vit E 5-fluorouracil   | Human (41)       | –                   | –                               | Yes              | Pyrhonen et al. (1995) |
| Antioxidant nutrients            | Human (58)       | Yes                 | Yes                             | –                | Copeland et al. (1978) |
| Vit A, Beta carotene, Vit E and Selenium | Human (18)       | Yes                 | Yes                             | Yes              | Jakkola et al. (1992) |
| Vit C, Vit E, Carotene and Selenium | Human (32)       | Yes                 | Yes                             | Yes              | Lockwood et al. (1994) |
| Vit C, E and Glutathione 5-fluorouracil, Peplomycin | Human (63)       | Yes                 | Yes                             | –                | Osaki et al. (1994) |
| Vit A and Vit E 5-fluorouracil, Epidermocin, Methotrexate | Human (41)       | Yes                 | –                               | Yes              | Pyrhonen et al. (1995) |
| Vit A, Vit C and Vit E Chemotherapy (site appropriate) | Human (20)       | Yes                 | Yes                             | –                | Sakamoto et al. (1983) |
| Vit A, Vit C, Vit E and Selenium | Human (63)       | Yes                 | –                               | –                | Thirunavagadam et al. (1996) |
| Acetyl cysteine, Vit C and Vit E | Human (14)       | Yes                 | –                               | –                | Wadgi et al. (1995) |
| Vit C and Vit K 5-fluorouracil, Doxorubicin, 5-fluorouracil, Procarbazine, Asparginse | Human (25)       | No difference       | Yes                             | –                | Chinery et al. (1997) |
| Vit C and Vit E Mixed chemotherapy | Human (136)      | No difference       | No difference                   | No difference    | Wadgi et al. (1996) |
| Antioxidant mixtrue, Vit C, Vit E and β-carotene | Human (2)        | Yes                 | Yes                             | –                | Pathak et al. (2005) |
| Vit A, Vit E, Coenzyme Q10, Vit C, β- carotene | Human (2)        | Yes                 | Yes                             | –                | Jeanne Drisko et al. (2003) |
| Vit C and E 5-fluorouracil, Doxorubicin, Cyclophosphamide 5-fluorouracil | Human (40)       | Yes                 | Yes                             | –                | Suhail et al. (2012) |
| 13-cis-retinoic acid and Vit D3 | Human (40)       | Yes                 | Yes                             | –                | Dalirhsani et al. (2012) |
| Vit C and Vit E Doxorubicin       | Animal (2)       | Yes (dose dependent) | Yes (dose dependent)            | –                | Antunes et al. (1998) |
| Riboflavin, Niacin and Co-enzyme Q10 | Animal (2)       | Yes                 | Yes                             | –                | Perumala et al. (2005) |
| Vit D3 and Retinoic Acid          | Animal (2)       | No decrease in tumor size | –                               | –                | Jorgensen et al. (2013) |

(n) = number of subjects involved in clinical study.
4. Discussion

The advent of modern cancer treatments has substantially improved the survival rate of patients. The enhancement in survival reflects progress in early stage diagnosis and use of combination chemotherapy. However, chemotherapeutic agents are associated with toxicity due to their potential to target rapidly dividing normal cells in the body. The prime concern of chemotherapy is drug associated oxidative stress, which results in many side effects.

Use of antioxidants can be beneficial in this respect as they minimize the burden of free reactive radicals in cells and thus can decrease the duration of chemotherapy regimens. Despite nearly two decades of research investigating the use of dietary antioxidant supplementation during conventional chemotherapy, controversy remains about the efficacy and safety of this complementary treatment. Several randomized clinical trials have demonstrated that the concurrent administration of antioxidants with chemotherapy reduces treatment-related side effects. Some data indicate that antioxidants may protect tumor cells as well as healthy cells from oxidative damage generated by some chemotherapeutic agents. However, other data suggest that antioxidants can protect normal tissues from chemotherapeutic induced damage without decreasing tumor control.

The lack of enthusiasm among clinical oncologists for using high doses of antioxidant vitamins in combination with chemotherapy is primarily based on fear that antioxidant vitamins may protect both normal and cancer cells against free radicals which are generated by most of the chemotherapeutic agents. Often there is disagreement on how antioxidant protect normal cells against damage from cancer therapy, while not affecting or increasing their cytotoxic effect against malignant cells? Answer to this question is not entirely figured out, but there are certain concepts which might help us understand. One is that if generation of ROS by cancer chemotherapeutic agent or a free radical intermediate of the drug plays a role in its cytotoxicity, antioxidant may interfere with the drug’s antineoplastic activity. However, if the reactive species are responsible only for drug’s adverse effects, antioxidant may actually reduce the severity of such effect without interfering with the drug’s antineoplastic activity. Thus, it is important to distinguish between a drug’s ability to induce oxidative stress in biological system and the role, if any, that ROS or free radicals intermediate play in the mechanism of action of the drug. Second concept why antioxidants are found to increase drug’s cytotoxic effect against malignant cells is that, chemotherapy often harms DNA, which causes the cells to undergo apoptosis, rather than necrosis. Since many antioxidant treatments stimulate apoptotic pathways, the potential exists for a complementary effect with chemotherapy and antioxidants. The third view is that, defensive mechanisms of many cancer cells are known to be impaired. This presumably makes tumor cells unable to use the extra antioxidants in a repair capacity.

The clinical cancer research community should cooperate and focus new studies on the use of a specific combination of antioxidant in chemotherapy, and determine optimal doses of antioxidant for a specific cancer setting. Mechanistic studies on the interaction between antioxidants and conventional cancer therapy could also lead to novel biomarkers for assessing dose adequacy.

Conflict of interest

Authors declare no conflict of interest. Authors declare full control of all primary data.

Acknowledgment

Authors acknowledge Late Dr. J. Nadkarni for her support.

References

Adwankar, M., Banerji, A., Ghosh, S., 1991. Differential response of retinoic acid pretreated human synovial sarcoma cell line to anticancer drugs. Tumori 77, 351–354.
Alexieva, B., Markova, T., Nikolova, E., Aragan, Y., Higashino, H., 2010. Free radicals, antioxidants and cancer chemotherapy. Acta. Med. Kinki. Univ. 35, 57–65.
Antunesa, L.M., Takahashia, C.S., 1998. Effect of high doses of vitamins C and E against doxorubicin-induced chromosomal damage in Wistar rat bone marrow. Cytogenet. Cell Genet. 119, 137–140.
Argyriou, A.A., Chroni, E., Koutras, A., Iconomou, G., Papapetropoulos, S., Polychronopoulous, P., Kalofonos, H.P., 2006a. A randomized controlled trial evaluating the efficacy and safety of vitamin E supplementation for protection against cisplatin induced peripheral neuropathy: final results. Support Care Cancer 14, 1134–1140.
Argyriou, A.A., Chroni, E, Koutras, A., Iconomou, G., Papapetropoulos, S., Polychronopoulous, P., Kalofonos, H.P., 2006b. Preventing paclitaxel-induced peripheral neuropathy: a phase II trial of vitamin E supplementation. J. Pain Symptom Manage. 32, 237–244.
Bannwarth, B., Labat, L., Moride, Y., Schaerbeke, T., 1994. Methotrexate in rheumatoid arthritis. An update. Drugs 47, 25–50.
Bao, A., Li, Y., Tong, Y., Zheng, H., Wu, W., Wei, C., 2014. 1,25-Dihydroxyvitamin D3 and cisplatin synergistically induce apoptosis and cell cycle arrest in gastric cancer cells. Int. J. Mol. Med. 33, 1177–1184.
Beckman, K.B., Ames, B.N., 1997. Oxidative decay of DNA. J. Biol. Chem. 272, 19633–19636.
Bello, S.O., Chika, A., 2009. Dose-dependent amelioration of gentamicin-induced nephrotoxicity in adult swiss albino rats by vitamin b-complex – a preliminary study. Trop. J. Pharm. Res. 8, 111–116.
Berry, J.P., Pauwella, C., Touzeau, S., et al., 1984. Effect of selenium in combination with cisdiaminedichloroplatinum (II) in the treatment of murine fibrosarcoma. Cancer Res. 44, 2684–2688.
Besal, E.C., Abrahin, L.L., Braswell, E.C., Hynzinski, M., Nowell, P.C., 1990. Treatment with 13 cis retinoic acid in transfusion-dependent patients with myelodysplastic syndrome and decreased toxicity with addition of alphatocopherol. Am. J. Med. 89, 739–747.
Bjelalovic, G., Nikolova, D., Glud, LL, Simonetti, R.G., Glud, C., 2007. Mortality in randomized trials of antioxidant supplements for primary and secondary prevention: systematic review and meta-analysis. JAMA 297, 842–857.
Block, K.I., Koch, A.C., Mead, M.N., Tothy, P.K., Newman, R.A., Gyllenhaal, C., 2008. Impact of antioxidant supplementation on chemotherapeutic toxicity: a systematic review of the evidence from randomized controlled trials. Int. J. Cancer 123, 1227–1239.
Bodén, C., Marzorati, L., Marzola, M., et al., 1996. Neurotoxicity of cisplatin +/- reduced glutathione in the first-line treatment of advanced ovarian cancer. Int. J. Gynaecol. Cancer 6, 415–419.
Bohm, S., Battista Spatti, G., Di Re, F., et al., 1991. A feasibility study of cisplatin administration with low-volume hydration and glutathione protection in the treatment of ovarian carcinoma. Anticancer Res. 11, 1613–1616.
Bohm, S., Oriana, S., Spatti, C., et al., 1999. Dose intensification of platinum compounds with glutathione protection as induction chemotherapy for advanced ovarian carcinoma. Oncology 57, 115–120.
Boucher, F., Coudray, C., Tirard, V., et al., 1995. Oral selenium supplementation in rats reduces cardiac toxicity of adriamycin during ischemia and reperfusion. Nutrition 11, 708–711.
Budd, G.T., Adamson, P.C., Gupta, M., et al., 1998. Phase III trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin. Cancer Res. 4, 635–642.
Casado-Zapico, S., Rodriguez-Blanco, J., Garcia-Santos, G., Martin, V., Sanchez-Sanchez, A.M., Antolin, I., Rodriguez, C., 2010. Synergistic antitumor effect of melatonin with several chemotherapeutic drugs on human Ewing sarcoma cancer cells: potentiation of the extrinsic apoptotic pathway. J. Pineal Res. 48, 72–80.
Cascinu, S., Cordellia, L., Del Ferro, E., et al., 1996. Neuroprotective effect of reduced glutathione on cisplatin-based chemotherapy in advanced gastric cancer: a randomized double-blind placebo-controlled trial. J. Clin. Oncol. 13, 26–32.
Cascinu, S., Labianca, R., Graziano, F., et al., 1988. Intensive weekly chemotherapy in patients with stages I-IIIB of non-small cell lung cancer. J. Gynaecol. Cancer 6, 415–419.
Cascinu, S., Cordella, L., Fabris, C., et al., 1995. Randomized, double-blind placebo-controlled trial. J. Clin. Oncol. 13, 26–32.
Cascinu, S., Labianca, R., Graziano, F., et al., 1988. Intensive weekly chemotherapy for locally advanced gastric cancer using 5-fluorouracil, cisplatin, epidermorubcin, 65-levoucorin, glutathione and filgrastim: a report from the Italian Group for the Study of Digestive Tract Cancer (GISCAD). Br. J. Cancer 78, 390–393.
Cascinu, S.C.V., Cordellia, L., Labianca, R., et al., 2002. Neuroprotective effect of reduced glutathione on oxaliplatin- based chemotherapy in advanced colorectal cancer: a randomized, double-blind placebo-controlled trial. J. Clin. Oncol. 20, 3478–3483.
Cerezo, G., Vaghli, M., Ardizzone, A., et al., 2002. Biomodulation of cancer chemotherapy for metastatic colorectal cancer: a randomized study of weekly low-dose irinotecan alone versus irinotecan plus the oncostatic pineal hormone melatonin in metastatic colorectal cancer patients progressing on 5-fluorouracil containing combination. Anticancer Res. 23, 1951–1954.
Ganser, A., Maurer, A., Contzen, C., et al., 1996. Improved multilineage response of
Di Re, F., Bohm, S., Oriana, S., Spatti, G.B., Zunino, F., 1990. Efficacy and safety of
determine the prevention of chemotherapy-induced peripheral neuropathy: results of a randomised phase III clinical trial. Support Care Cancer 19, 1769–1777.
Moss, R.W., 2007. Do antioxidants interfere with radiation therapy for cancer? Int. J. Radiat. Oncol. Biol. Phys. 68, 1746–1753.
Moss, R.W., 2008. Do antioxidants interfere with radiation therapy for cancer? J. Clin. Oncol. 26, 3011–3015.
Moss, R.W., 2009. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 43, 92–95.
Moss, R.W., 2010. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 44, 102–105.
Moss, R.W., 2011. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 45, 113–116.
Moss, R.W., 2012. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 49, 124–127.
Moss, R.W., 2013. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 50, 132–135.
Moss, R.W., 2014. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 51, 144–147.
Moss, R.W., 2015. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 52, 158–161.
Moss, R.W., 2016. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 53, 168–171.
Moss, R.W., 2017. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 54, 178–181.
Moss, R.W., 2018. Do antioxidants interfere with radiation therapy for cancer? J. Radiol. Oncol. 55, 188–191.
Singh, K., Mhatre, V., Bhor, M., Marar, T., 2013. Vitamin E and C reduces oxidative stress and mitochondria permeability transition generated by camptothecin- an in vitro study. J. Toxicol. Environ. Chem. 95, 646–657.
Singh, K., Pillai, V., Marar, T. 2012b. Influence of vitamin E on camptothecin induced oxidant injury-An in vitro study on erythrocytes. J. Pharm. Res. 5, 3116–3119.
Singh, K.C., Marar, T. 2011. Acute toxicity of Camptothecin and influence of α-tocopherol on hematological and biochemical parameters. J. Cell Tissue Res. 11, 287–287.
Singh, K.C., Kaur, R., Marar, T. 2011b. Ameliorative effect of vitamin E on chemotherapy induced side effects in rat liver. J. Pharmocol. Toxicol. 6, 481–481.
Slavik, M., Sailer, J.H., 1983. Phase I clinical study of acetylcysteinine's preventing ifosfamide- induced hematuria. Semin. Oncol. 10, 62–65.
Smyth, J.F., Bowman, A., Parren, T., et al., 1997. Glutathione reduces the toxicity and improves quality of life in women diagnosed with ovarian cancer treated with cisplatin: results of a double-blind, randomised trial. Ann. Oncol. 8, 569–573.
Sonneveld, P., 1978. Effect of alpha-tocopherol on the cardio toxicity of Adriamycin in the rat. Cancer Treat. Rep. 62.

Sue, K., Nakagawa, A., Okuzono, S.I., et al., 1988. Combined effects of vitamin E (alpha tocopherol) and cisplatin on the growth of murine neuroblastoma in vivo. Eur. J. Cancer Clin. Oncol. 24, 1751–1758.
Suhail, N., Bilal, N., Khan, H.Y., Hasan, S., Sharma, S., Khan, F., Mansoor, T., Banu, N. 2012. Effect of vitamins C and E on antioxidant status of breast-cancer patients undergoing chemotherapy. J. Clin. Pharm. Ther. 37, 22–26.
Switalska, M., Nasuiewicz-Goldenman, A., Opolska, A., Maciejewska, M., Kutner, A., Wrona, M., 2012. The pro-oxidative and pro-inflammatory effect of DHC-219 and inspection Rollier, A., Wellmer, M., 1998. Antioxidants specifically inhibit cisplatin cytotoxicity of human malignant glioma cells. Anticancer Res. 18, 4493–4497.
Sakamoto, A., Choungue, P.B., Prasad, K.N., 1983. Retrospective analysis of the effect of vitamin A, C and E on human neoplasms. In: Prasad, K.N. (Ed.), Medulation of Nutrition and Cancer. Karger Press, New York, pp. 2–19.
Santamaría, L., Bianchi-Santamaría, A., dell’Orti, M., 1996. Carotenoids in cancer, mastalgia, and AIDS: prevention and treatment—an overview. J. Environ. Pathol. Toxicol. Oncol. 15, 89–97.
Scambia, G., Ranelletti, F.O., Panici, P.B., et al., 1994. Quercetin potentiates the effect of 5FU, folinic acid, epirubicin, mitomycin-C, beta-interferon and retinol palmitate in patients with unresectable pancreatic carcinoma. Proc. Ann. Meet. Am. Assoc. Cancer. Res. 33, A1296.
Recchia, F., Rea, S., Ferrari, F., Roselli, M., Corrao, G., Gulino, A., Sica, G., 1998. Beta-interferon, retinoids, and tamoxifen combination in advance breast cancer. Clin. Ter. 149, 203–208.
Recchia, F., Rea, S., Pompili, P., et al., 1995a. Beta-interferon, retinoids and tamoxifen as maintenance therapy in metastatic breast cancer. A pilot study. Clin. Ter. 146, 603–610.
Recchia, F., Serafini, F., Rea, S., Frati, L., 1995b. Phase II study of SFU, follicinic acid, epirubicin, mitomycin-C, beta-interferon and retinol palmitate in patients with unresectable pancreatic carcinoma. Proc. Ann. Meet. Am. Assoc. Cancer. Res. 33, A1296.
Recchia, F., Sica, G., De Filippis, S., Discipio, S., Rea, S., Torchio, P., Frati, L., 1999b. Interferon-beta, retinoids, and tamoxifen in the treatment of metastatic breast cancer. Proc. Phase II. Interferons. Cytokines. Cancer Chemother. and Interferon Curr. Res. 1, 141–144.
Recchia, F., Lelli, S., DiMatteo, G., Rea, S., Frati, L., 1993b. SFU, cisplatin and retinol palmitate in the management of advanced cancer of the oral cavity. Phase II study. Clin. Ter. 142, 403–409.
Recchia, F., Rea, S., Filippelli, M., Recchia, F., Corrao, G., Gulino, A., Sica, G., 1998. Beta-interferon, retinoids, and tamoxifen combination in advance breast cancer. Clin. Ter. 149, 203–208.

Simone 2nd, C.B., Simone, N.L., Simone, V., Simone, C.B., 2007a. Antioxidants and oxidative stress: a review. J. Dent. Allied. Sci. 1, 63–66.
Simone 2nd, C.B., Simone, N.L., Simone, V., Simone, C.B., 2007b. Antioxidants and oxidative stress: part I. Altern. Ther. Health Med. 13, 22–28.
Simone 2nd, C.B., Simone, N.L., Simone, V., Simone, C.B., 2007c. Antioxidants and oxidative stress: part II. Altern. Ther. Health Med. 13, 40–48.
Singh, K., Pillai, V., Marar, T. 2012a. Influence of vitamin E on camptothecin induced oxidative stress in the small intestine of rats. J. Pharm. Res. 5, 5460–5484.
Singh, K., Malviya, A., Bhor, M., Marar, T., 2012. Prophylactic role of vitamin E on camptothecin induced oxidative stress in rat heart mitochondria. J. Basic Clin. Physiol. Pharmacol. 23, 163–168.
Singh, K., Marar, T., 2012. Prophylactic role of vitamin E on camptothecin induced oxidative stress in the small intestine of rats. J. Pharm. Res. 5, 5460–5484.
Schwenke, D.C., 2002. Does lack of tocopherols and tocotrienols put women at increased risk of breast cancer? T. Nutr. Biochem. 13, 2–20.
Shinde, A., Ganu, J., Naik, P., 2012. Effect of free radicals and antioxidant on chemotherapy. In: Antioxidants and Free Radicals: A Practical Approach. Humana Press, pp. 1–25.
Shimizu, K., Hamaguchi, Y., Fujita, Y., 2005. Alterations in rats treated with camptothecin and propylphophylic effect of α-tocopherol. J. Cell Tissue Res. 11, 2955–2959.
Singh, K., Malviya, A., Bhor, M., Marar, T., 2012a. An in vitro study of the ameliorative role of α-tocopherol on methotrexate- induced oxidative stress in rat heart mitochondria. J. Basic Clin. Physiol. Pharmacol. 23, 163–168.
Singh, K., Marar, T., 2012. Prophylactic role of vitamin E on camptothecin induced oxidative stress in the small intestine of rats. J. Pharm. Res. 5, 5460–5484.
Weitzman, S.A., Lorell, E., Carey, R.W., Kaufman, S., Stossel, T.P., 1980. Prospective studies of Tocopherol prophylaxis for anthracycline cardiac toxicity. Curr. Ther. Res. 28, 682–686.

Wiernik, P.H., Yeap, B., Vogl, S.E., et al., 1992. Hexamethylmelamine and low or moderate dose cisplatin with or without pyridoxine for the treatment of advanced ovarian carcinoma: a study of the Eastern Cooperative Oncology Group. Cancer Invest. 10, 1–9.

Wietrzyk, J., Nevozhay, D., Milczarek, M., Filip, B., Kutner, A., 2008. Toxicity and antitumor activity of the vitamin D analogs PRI-1906 and PRI-1907 in combined treatment with cyclophosphamide in a mouse mammary cancer model. Cancer Chemother. Pharmacol. 62, 787–797.

Winterbourn, C.C., 2008. Reconciling the chemistry and biology of reactive oxygen species. Nat. Chem. Biol. 4, 278–286.

Wood, L.A., 1985. Possible prevention of adriamycin-induced alopecia by tocopherol. N. Engl. J. Med. 312, 1060.

Yoshida, T., Miyazawa, K., Kasuga, I., Yokoyama, T., Minemura, K., Ustumi, K., Aoshima, M., Ohyashiki, K., 2003. Apoptosis induction of vitamin K2 in lung carcinoma cell lines: the possibility of vitamin K2 therapy for lung cancer. Int. J. Oncol. 23, 627–632.

Zhang, K., Yang, E.B., Wong, K.P., Mack, P., 1999. GSH, GSH-related enzymes and GS-X pump in relation to sensitivity of human tumor cell lines to chlorambucil and adriamycin. Int. J. Oncol. 14, 861–867.